Disease-modifying therapies and infectious risks in multiple sclerosis

被引：180

作者：

Winkelmann, Alexander ^{[1
]}

Loebermann, Micha ^{[2
]}

Reisinger, Emil C. ^{[2
]}

Hartung, Hans-Peter ^{[3
]}

Zettl, Uwe K. ^{[1
]}

机构：

[1] Univ Rostock, Dept Neurol, Gehlsheimer Str 20, D-18147 Rostock, Germany

[2] Univ Rostock, Dept Trop Med & Infect Dis, Ernst Heydemann Str 6, D-18057 Rostock, Germany

[3] Univ Dusseldorf, Dept Neurol, Moorenstr 5, D-40225 Dusseldorf, Germany

来源：

NATURE REVIEWS NEUROLOGY | 2016年 / 12卷 / 04期

关键词：

PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; THERAPEUTIC LYMPHOCYTE DEPLETION; DOUBLE-FILTRATION PLASMAPHERESIS; PLACEBO-CONTROLLED PHASE-3; ZOSTER-VIRUS INFECTIONS; DOUBLE-BLIND; INTERFERON-BETA; PLASMA-EXCHANGE; ORAL TERIFLUNOMIDE; INTRAMUSCULAR INTERFERON;

D O I：

10.1038/nrneurol.2016.21

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Immunomodulatory and immunosuppressive treatments for multiple sclerosis (MS) are associated with an increased risk of infection, which makes treatment of this condition challenging in daily clinical practice. Use of the expanding range of available drugs to treat MS requires extensive knowledge of treatment-associated infections, risk-minimizing strategies and approaches to monitoring and treatment of such adverse events. An interdisciplinary approach to evaluate the infectious events associated with available MS treatments has become increasingly relevant. In addition, individual stratification of treatment-related infectious risks is necessary when choosing therapies for patients with MS, as well as during and after therapy. Determination of the individual risk of infection following serial administration of different immunotherapies is also crucial. Here, we review the modes of action of the available MS drugs, and relate this information to the current knowledge of drug-specific infectious risks and risk-minimizing strategies.

引用

页码：217 / 233

页数：17

共 251 条

[31] Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 3 Treatment practicalities and recommendations [J].

Broadley, Simon A. ;

Barnett, Michael H. ;

Boggild, Mike ;

Brew, Bruce J. ;

Butzkueven, Helmut ;

Heard, Robert ;

Hodgkinson, Suzanne ;

Kermode, Allan G. ;

Lechner-Scott, Jeannette ;

Macdonell, Richard A. L. ;

Marriott, Mark ;

Mason, Deborah F. ;

Parratt, John ;

Reddel, Stephen W. ;

Shaw, Cameron P. ;

Slee, Mark ;

Spies, Judith ;

Taylor, Bruce V. ;

Carroll, William M. ;

Kilpatrick, Trevor J. ;

King, John ;

McCombe, Pamela A. ;

Pollard, John D. ;

Willoughby, Ernest .

JOURNAL OF CLINICAL NEUROSCIENCE, 2014, 21 (11) :1857-1865

[32] Mitoxantrone repression of astrocyte activation: Relevance to multiple sclerosis [J].

Burns, Samuel A. ;

Archer, R. Lee ;

Chavis, Janet A. ;

Tull, Cameron A. ;

Hensley, Lori L. ;

Drew, Paul D. .

BRAIN RESEARCH, 2012, 1473 :236-241

[33]

Buttgereit F, 2012, BULL HOSP JT DIS, V70, pS26

[34] Exogenous and Endogenous Glucocorticoids in Rheumatic Diseases [J].

Buttgereit, Frank ;

Burmester, Gerd-Ruediger ;

Straub, Rainer H. ;

Seibel, Markus J. ;

Zhou, Hong .

ARTHRITIS AND RHEUMATISM, 2011, 63 (01) :1-9

[35] Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study [J].

Calabresi, Peter A. ;

Kieseier, Bernd C. ;

Arnold, Douglas L. ;

Balcer, Laura J. ;

Boyko, Alexey ;

Pelletier, Jean ;

Liu, Shifang ;

Zhu, Ying ;

Seddighzadeh, All ;

Hung, Serena ;

Deykin, Aaron .

LANCET NEUROLOGY, 2014, 13 (07) :657-665

[36] Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates [J].

Caliceti, P ;

Veronese, FM .

ADVANCED DRUG DELIVERY REVIEWS, 2003, 55 (10) :1261-1277

[37]

Carbone J, 2011, EXPERT REV ANTI-INFE, V9, P405, DOI [10.1586/ERI.10.178, 10.1586/eri.10.178]

[38] Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project [J].

Carson, Kenneth R. ;

Evens, Andrew M. ;

Richey, Elizabeth A. ;

Habermann, Thomas M. ;

Focosi, Daniele ;

Seymour, John F. ;

Laubach, Jacob ;

Bawn, Susie D. ;

Gordon, Leo I. ;

Winter, Jane N. ;

Furman, Richard R. ;

Vose, Julie M. ;

Zelenetz, Andrew D. ;

Mamtani, Ronac ;

Raisch, Dennis W. ;

Dorshimer, Gary W. ;

Rosen, Steven T. ;

Muro, Kenji ;

Gottardi-Littell, Numa R. ;

Talley, Robert L. ;

Sartor, Oliver ;

Green, David ;

Major, Eugene O. ;

Bennett, Charles L. .

BLOOD, 2009, 113 (20) :4834-4840

[39] Azathioprine for multiple sclerosis [J].

Casetta, I. ;

Iuliano, G. ;

Filippini, G. .

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2009, 80 (02) :131-132

[40]

Casetta I., 2007, COCHRANE DB SYST REV, V4

← 1 2 3 4 5 6 7 8 9 10 →